contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lidds-ab-publ-interim-report-january-march-2024-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

LIDDS

 First quarter 2024 (the Group) ·Net sales amounted to 0 (0) TSEK ·The operating result for the period was -1 254 (-1) TSEK ·The net result was -1 311 (-5) TSEK corresponding to earnings per...

<div class="mfn-body"> First quarter 2024 (the Group) ·Net sales amounted to 0 (0) TSEK ·The operating result for the period was -1&nbsp;254 (-1) TSEK ·The net result was -1&nbsp;311 (-5) TSEK corresponding to earnings per share of -0,01 (-0.00) SEK ·Cash flow from operating activities amounted to -738 (-64) TSEK ·Cash and cash equivalents amounted to 4 768 (10&nbsp;947) TSEK &nbsp; Significant events after the reporting period (during April) ·On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. ·Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024. ·Due to the reasons to believe that the company’s equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22. ·The balance sheet for liquidation purpose prepared and reviewed by the company’s auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting. CEO statement During the first quarter, the focus has continued to be on trying to commercialize the three projects Nanoimod, Nanodotax and NOV 202. Furthermore, the work to reduce the company's costs has continued. In beginning of April, we finally concluded, after extensive attempts, that Lidds will not succeed with the investments on which we have concentrated the company's resources on and therefore we did not see any opportunity to capitalize the company for further clinical studies. As a result, the board of directors decided to terminate further development of these project areas. The work will now be fully focused on utilizing the values that the company owns in the form of the NanoZolid technology platform and its patents, the subsidiary Noviga with the drug candidate NOV 202 and its patents. In addition, we will investigate the interest for the company's listing on First North and any values for the accumulated loss carry forwards that have arisen. Mats Wiking CEO and CFO The interim report is available on the company’s website <a rel="noopener" href="https://liddspharma.com/sv/investerare/finansiella-rapporter/">https://liddspharma.com/sv/investerare/finansiella-rapporter/</a></div><div class="mfn-footer mfn-contacts mfn-cb73eb895ad4">For additional information, please contact<hr>Mats Wiking, CEO and CFO Phone: +46 (0)70 620 04 00 E-mail: mats.wiking<a rel="noopener" href="mailto:jenni.bjornulfson@liddspharma.com">@liddspharma.com</a>LIDDS’ Certified Adviser is Redeye AB</div><div class="mfn-footer mfn-about mfn-dcb9e4cb41ff">LIDDS in brief:<hr>LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/6f9d40bb-aa06-4d10-811c-8f315fe2cfa9/lidds-interim-report-q1-2025.pdf" class="mfn-primary">LIDDS Interim Report Q1 2025</a></div>